Dana-Farber Cancer Institute

Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.

Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.

David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been named to the National Academy of Medicine.

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.

U.S. News & World Report has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation.

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

T-DXd shows substantial antitumor activity in brain metastases in patients with HER2-positive breast cancer in a major international clinical trial.

The SOLARIS trial results suggest that high-dose vitamin D3 cannot be recommended as a treatment for patients with untreated metastatic colon cancer.

Laurie H. Glimcher, MD, announced today that she will step down as Dana-Farber Cancer Institute President and CEO on October 1, 2024, and will assume the title of President Emerita.

The study alters the existing paradigm that CDK1-Cyclin B1 is the only CDK-cyclin complex essential for all stages of mitosis.

Systematic identification of minor histocompatibility antigens informs outcomes after allogeneic stem cell transplantation.

Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.

Botensilimab plus balstilimab generated responses in relapsed/refractory microsatellite stable metastatic colorectal cancer.

Dana-Farber Cancer Institute is proud to announce the launch of the Direct Connect Partnership with Massachusetts Firefighters, addressing the heightened cancer risk faced by firefighters.

A study found stage 3 colon cancer patients with PIK3CA mutations taking celecoxib post-surgery had longer survival and disease-free intervals.

Dana-Farber Cancer Institute investigators have found that people experience discrimination in different ways and in various realms of cancer care.

Most young breast cancer survivors can go on to have children despite the effects of their lifesaving treatment, a new study shows.

Physician-scientists at Dana-Farber Cancer Institute have received a 5-year, $15 million Program Project Grant from the NCI for research in endometrial cancer

A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.

In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases of AI.

The American Nurses Credentialing Center has awarded Magnet® status to Dana-Farber Cancer Institute for the 5th time in a row.

Dana-Farber details how their Neuro-Inclusive Oncology Care and Empowerment program was developed to help physicians and other providers treat cancer in patients who have intellectual and/or developmental disabilities.

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.

In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.

The Third Transatlantic Exchange in Oncology Conference will focus on liquid biopsy as an emerging approach in precision cancer medicine.

Different immunomodulatory mechanisms are at work depending on the type of treatment and the genetic makeup of the cancer in RCC.

Catherine J. Wu, MD, of Dana-Farber Cancer Institute, has been awarded the Sjöberg Prize today for her pioneering research in the field of personalized vaccines to treat cancer.